Online citations, reference lists, and bibliographies.
← Back to Search

Therapeutic Implications Of The MDR-1 Gene.

K. Mealey
Published 2004 · Biology, Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
Drug transporters significantly influence drug pharmacokinetics and pharmacodynamics. P-glycoprotein (P-gp), the product of the MDR1 (ABCB1) gene, is among the most well-characterized drug transporters, particularly in veterinary medicine. A number of clinically relevant, structurally and functionally unrelated drugs are substrates for P-gp. P-gp is expressed by a variety of normal tissues including the intestines, renal tubular cells, brain capillary endothelial cells, biliary canalicular cells, and others, where it functions to actively extrude substrate drugs. In this capacity, P-gp limits oral absorption and central nervous system entry of many substrate drugs. A number of MDR1 polymorphisms have been described in human patients, some of which result in altered drug pharmacokinetics and susceptibility to diseases such as Parkinson's disease, inflammatory bowel disease, refractory seizures, and others. An MDR1 polymorphism in herding breed dogs, including collies and Australian shepherds, has been demonstrated to be the cause of ivermectin sensitivity in these breeds. Recent evidence suggests that this polymorphism, a 4-bp deletion mutation, results in increased susceptibility to the toxicity of several drugs in addition to ivermectin. Furthermore, data in rodent models suggest that P-gp may play an important role in regulating the hypothalamic-pituitary-adrenal axis.
This paper references
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants.
R. Juliano (1976)
Cellular localization of the multidrug-resistance gene product P-glycoprotein in normal human tissues.
F. Thiebaut (1987)
Clinical observations in collies given ivermectin orally.
A. Paul (1987)
Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine.
K. Ueda (1987)
P‐glycoprotein: multidrug‐resistance and a superfamily of membrane‐associated transport proteins
P. Juranka (1989)
Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.
C. Cordon-Cardo (1989)
Expression and Functions of P‐glycoprotein (mdr 1 gene product) in Normal and Malignant Tissues
I. Sugawara (1990)
Safety and efficacy of loperamide.
C. Ericsson (1990)
What determines the substrate specificity of the multi-drug-resistance pump?
I. West (1990)
Assessment of toxicosis induced by high-dose administration of milbemycin oxime in collies.
W. Tranquilli (1991)
Molecular biology of P-glycoprotein.
M. M. Cornwell (1991)
The role of the MDR1 (P-glycoprotein) gene in multidrug resistance in vitro and in vivo.
I. Roninson (1992)
Modulation of activity of the promoter of the human MDR1 gene by Ras and p53.
K. Chin (1992)
Role of P-glycoprotein in renal tubular secretion of digoxin in the isolated perfused rat kidney.
R. Hori (1993)
Immunohistochemical detection of P-glycoprotein and GSTP1-1 in testis cancer.
A. Katagiri (1993)
Clinical trials of agents that reverse multidrug resistance. A literature review
M. Raderer (1993)
Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
A. Schinkel (1994)
Functional complementation of the ste6 gene of Saccharomyces cerevisiae with the pfmdr1 gene of Plasmodium falciparum.
S. Volkman (1995)
Absence of the mdr1a P-Glycoprotein in mice affects tissue distribution and pharmacokinetics of dexamethasone, digoxin, and cyclosporin A.
A. Schinkel (1995)
Multidrug resistance and the role of P-glycoprotein knockout mice.
A. Schinkel (1995)
Loperamide poisoning in the dog.
C. Hugnet (1996)
Non-P-glycoprotein drug export mechanisms of multidrug resistance.
A. List (1997)
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine.
A. Sparreboom (1997)
Role of intestinal P‐glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine
Kenneth S. Lown (1997)
Doxorubicin induced expression of P-glycoprotein in a canine osteosarcoma cell line.
K. Mealey (1998)
Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice.
G. Lankas (1998)
The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.
R. Kim (1998)
Effect of ketoconazole on cyclosporine dose in healthy dogs.
J. Dahlinger (1998)
A general pattern for substrate recognition by P-glycoprotein.
A. Seelig (1998)
The ABC family of multidrug transporters in microorganisms.
H. V. van Veen (1998)
The roles of P‐glycoprotein and intracellular metabolism in the intestinal absorption of methadone: in vitro studies using the rat everted intestinal sac
R. Bouër (1999)
Unexpected effect of verapamil on oral bioavailability of the β‐blocker talinolol in humans
Ute I. Schwarz (1999)
Disposition of ivermectin and cyclosporin A in CF-1 mice deficient in mdr1a P-glycoprotein.
G. Kwei (1999)
Regulation and expression of multidrug resistance (MDR) transcripts in the intestinal epithelium
M. Li (1999)
Effect of PSC 833, a P-glycoprotein modulator, on the disposition of vincristine and digoxin in rats.
S. Song (1999)
P‐glycoprotein, lung resistance‐related protein and multidrug resistance associated protein in de novo acute non‐lymphocytic leukaemias: biological and clinical implications
M. Michieli (1999)
Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption
M. Uhr (2000)
Pharmacological inhibition of P-glycoprotein transport enhances the distribution of HIV-1 protease inhibitors into brain and testes.
E. Choo (2000)
Increased drug delivery to the brain by P‐glycoprotein inhibition
A. Sadeque (2000)
In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin.
E. D. de Lange (2000)
Modulation of P-glycoprotein-mediated doxorubicin resistance in canine cell lines.
R. Page (2000)
Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P‐glycoprotein
K. Westphal (2000)
Inhibitory effect of erythromycin on P-glycoprotein-mediated biliary excretion of doxorubicin in rats.
S. Kiso (2000)
Strategies to overcome simultaneous P-glycoprotein mediated efflux and CYP3A4 mediated metabolism of drugs.
J. Patel (2001)
The Gut as a Barrier to Drug Absorption
Y Zhang (2001)
Ivermectin sensitivity in collies is associated with a deletion mutation of the mdr1 gene.
K. Mealey (2001)
Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
H. Yamaguchi (2002)
Bacterial Multidrug Resistance Mediated by a Homologue of the Human Multidrug Transporter P‐glycoprotein
W. N. Konings (2002)
Penetration of Endogenous Steroid Hormones Corticosterone, Cortisol, Aldosterone and Progesterone into the Brain is Enhanced in Mice Deficient for Both mdr1a and mdr1b P‐Glycoproteins
M. Uhr (2002)
Multidrug Resistance Genes and P-Glycoprotein in the Testis of the Rat, Mouse, Guinea Pig, and Human1
N. Melaine (2002)
Cyclosporine and ketoconazole for the treatment of perianal fistulas in dogs.
A. J. Patricelli (2002)
Frequency of the mutant MDR1 allele associated with ivermectin sensitivity in a sample population of collies from the northwestern United States.
K. Mealey (2002)
P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice
G. Sills (2002)
Interaction of Morphine, Fentanyl, Sufentanil, Alfentanil, and Loperamide with the Efflux Drug Transporter P-glycoprotein
C. Wandel (2002)
MDR1 genotype-related pharmacokinetics and pharmacodynamics.
T. Sakaeda (2002)
Transport of paclitaxel (Taxol) across the blood-brain barrier in vitro and in vivo.
S. Fellner (2002)
Investigation of multidrug efflux pumps in relation to fluconazole resistance in Candida albicans biofilms.
G. Ramage (2002)
Genetically determined differences in P-glycoprotein function: implications for disease risk.
M. Fromm (2002)
P-glycoprotein in helminths: function and perspectives for anthelmintic treatment and reversal of resistance.
D. Kerboeuf (2003)
Efflux transporters of the human placenta.
Amber M. Young (2003)
Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
J. Allen (2003)
Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1.
A. Siddiqui (2003)
Pharmacogenetics of MDR1 and its impact on the pharmacokinetics and pharmacodynamics of drugs.
T. Sakaeda (2003)
Polymorphism in the P-glycoprotein drug transporter MDR1 gene: a possible link between environmental and genetic factors in Parkinson's disease.
M. Droździk (2003)
Treatment of Tourette Syndrome with Delta-9-Tetrahydrocannabinol (Δ9-THC): No Influence on Neuropsychological Performance
K. Müller-Vahl (2003)
ABCB1 (MDR1)-Type P-Glycoproteins at the Blood–Brain Barrier Modulate the Activity of the Hypothalamic–Pituitary–Adrenocortical System: Implications for Affective Disorder
M. Müller (2003)
Increased toxicity of P-glycoprotein-substrate chemotherapeutic agents in a dog with the MDR1 deletion mutation associated with ivermectin sensitivity.
K. Mealey (2003)
Genetic polymorphisms of the human MDR1 drug transporter.
M. Schwab (2003)
Association between the C3435T MDR1 gene polymorphism and susceptibility for ulcerative colitis.
M. Schwab (2003)
Enhanced bioavailability of oral docetaxel by co-administration of cyclosporin A in dogs and rats.
M. Mcentee (2003)
Frequency of the mutant MDR1 allele associated with multidrug sensitivity in a sample of collies from France.
C. Hugnet (2004)
Loperamide toxicity in a collie with the MDR1 mutation associated with ivermectin sensitivity.
L. L. Sartor (2004)
Differentiating effect of pamidronate on canine osteo-sarcoma cell lines in vitro
H. Lacoste (2004)
Polymorphisms in Human MDR1 (P‐glycoprotein): Recent Advances and Clinical Relevance
C. Marzolini (2004)
Pharmacologic circumvention of multidrug resistance
J. Ford (2004)
Effect of grapefruit juice on the pharmacokinetics of cyclosporine in dogs
F. Amatori (2004)
Breed distribution and history of canine mdr1-1Delta, a pharmacogenetic mutation that marks the emergence of breeds from the collie lineage.
M. Neff (2004)

This paper is referenced by
Clinical and Laboratory Findings in Dogs Undergoing Adjuvant Chemotherapy with Gemcitabine/Carboplatin Combination for Mammary Neoplasia. World Vet. J., 11 (2): 289-299.;
C. Israel (2021)
Lack of detectable short-term effects of a single dose of ivermectin on the human immune system
Natalie E Wilson (2021)
Evaluation of Prognostic Factors, including Duodenal P-Glycoprotein Expression, in Canine Chronic Enteropathy
M. Pietra (2021)
Tramadol Effects on Lameness Score After Inhibition of P-GP by Ivermectin Administration in Horses: Preliminary Results.
Fernando Silvério Ferreira da Cruz (2020)
Equine Drug Transporters: A Mini-Review and Veterinary Perspective
Brielle V Rosa (2020)
Preanaesthetic screening in dogs and cats
J. Ferreira (2020)
Effects of a rifampicin pre-treatment on linezolid pharmacokinetics
F. Okazaki (2019)
An investigation into the effect of clinical states of infection on pharmacokinetics and pharmacodynamics in ruminant food animal species
Joseph S. Smith (2019)
Role of ABC Transporters in Veterinary Medicine: Pharmaco- Toxicological Implications.
G. Virkel (2019)
Personalized medicine: going to the dogs?
K. Mealey (2019)
Effects of a rifampicin pre-treatment on linezolid pharmacokinetics
F. Okazaki (2019)
Drug Dose, Drug Choice: Optimizing Medical Therapy for Veterinary Cancer.
D. Thamm (2019)
Geographic distribution of the 3435C>T polymorphism of the MDR1 gene in Peruvian populations
Edward Valencia Ayala (2019)
Could polymorphisms in ABCB1 gene represent a genetic risk factor for the development of mammary tumors in dogs?
T. Maués (2019)
Avermectin toxicity in bovines less than thirty days old.
Daniel de Castro Rodrigues (2018)
Humanization of the Blood–Brain Barrier Transporter ABCB1 in Mice Disrupts Genomic Locus — Lessons from Three Unsuccessful Approaches
M. Krohn (2018)
Sick Oncology Patients in the Emergency Room
Kim Slensky (2018)
Suspected adverse reactions to oral administration of a praziquantel-pyrantel combination in captive cheetahs (Acinonyx jubatus).
K. Whitehouse-Tedd (2017)
Preparation of a generic monoclonal antibody and development of a highly sensitive indirect competitive ELISA for the detection of phenothiazines in animal feed.
J. Wang (2017)
High prevalence of epilepsy in onchocerciasis endemic regions in the Democratic Republic of the Congo
B. Levick (2017)
A functional model for feline P-glycoprotein.
C. D. van Beusekom (2016)
Helicobacter pylori and Antibiotic Resistance, A Continuing and Intractable Problem
Yue Hu (2016)
P‐Glycoprotein Mediated Drug Interactions in Animals and Humans with Cancer
K. Mealey (2015)
A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
D. Ito (2015)
The correlation of molecular phenotypes, chemotherapy response, and prognosis in cats with mammary carcinomas
T. Lo (2015)
MDR1-mutationen hos hundar
Johanna Olsson (2015)
Chapter 173 – Complications of Chemotherapy Agents
V. Larson (2015)
A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma.
D. Ito (2015)
Human Multidrug Resistance 1 gene polymorphisms and Idiopathic Pulmonary Fibrosis
M. Martinelli (2015)
Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy.
Renata Silva (2015)
A double blinded, placebo-controlled pilot study to examine reduction of CD34 +/CD117 +/CD133 + lymphoma progenitor cells and duration of remission induced by neoadjuvant valspodar in dogs with large B-cell lymphoma
D. Ito (2015)
Chapter 15 – Factors Influencing Analgesic Drug Selection, Dose, and Routes of Drug Administration
W. Muir (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar